The weight loss sector, a core focus in global innovative drug development, continues to attract leading industry players. Recently, TYK MEDICINES-B (02410) announced the formal nomination of its self-developed, next-generation oral small molecule GLP-1R agonist, TY-3002, as a preclinical candidate compound (PCC). TY-3002 is a breakthrough new molecule developed internally by TYK MEDICINES-B's R&D team based on deep insights into the GLP-1 receptor-ligand binding mechanism and structure, possessing "Best-in-Class" potential. It not only shows significant advantages in weight loss efficacy compared to existing first-generation oral small molecules but also demonstrates marked improvement in the quality of weight loss, positioning it to potentially redefine the standards for oral GLP-1 therapies.
Innovative Structural Design: Discovery of a Novel Anchor Point and Introduction of a Solubility Control Switch The development of oral small molecule GLP-1R agonists has long been hampered by complex spatial structure matching and extremely low molecular solubility. Leveraging deep research into GLP-1R small molecule binding and mechanism of action, combined with the advantages of CADD and AI technologies, TYK MEDICINES-B's R&D team successfully achieved two core structural innovations.
Breakthrough "Dual H-Bond Cap" Generation: Moving beyond existing understanding of GLP-1R small molecule binding regions, the team discovered an additional novel structural anchor point and successfully designed a "grasping" element, forming a unique "Dual H-Bond Cap" structure. This "cap" structure can precisely access additional key receptor sites not fully covered by Orforglipron. By forming an additional hydrogen bond network, TY-3002 effectively stabilizes the interface between the receptor's extracellular domain (ECD) and transmembrane domain (TMD). This extra structural anchoring may enhance downstream G protein signaling, laying the foundation for its superior in vivo efficacy.
Introduction of a "Switch" to Overcome Solubility Challenges: To address the industry-wide challenge of extremely low water solubility in existing GLP-1R small molecules, the R&D team introduced a proprietary "switch" into the molecular core scaffold. This "switch" significantly enhances the kinetic solubility of TY-3002, which not only improves bioavailability but also enables proportional oral absorption across different animal species and doses, better supporting future strategies for fixed-dose combinations and combination therapies.
Outstanding Weight Loss Efficacy: Crafting a High-Quality Weight Loss Solution Structural advantages ultimately translated into impressive efficacy data in animal models. In a head-to-head (H2H) study using hGLP-1R diet-induced obese (DIO) mice, which reflects clinical potential (1.0 mg/kg, oral, once daily, for 21 days), TY-3002 demonstrated superior weight loss effects. After 21 days of treatment, the TY-3002 group showed a highly significant body weight reduction of -31.51%, compared to a -22.82% reduction in the Orforglipron group at the same dose. After subtracting the natural -6.93% weight loss observed in the Vehicle control group, the net weight loss efficacy of TY-3002 (-24.58%) exceeded that of Orforglipron (-15.89%) by 54.6%.
Addressing a Core Challenge: High Fat Reduction with Relative Muscle Preservation A major challenge in the weight loss field is the loss of lean muscle mass alongside fat reduction, which can lead to decreased basal metabolism and weight rebound. While achieving greater weight reduction, TY-3002 exhibited excellent body composition regulation. TY-3002 not only reduced adipose tissue more significantly (fat proportion decreased to 21.4%) but also demonstrated a relative "muscle-sparing" effect, with lean mass proportion remaining high at 61.6%. This suggests TY-3002 could offer patients a higher-quality weight management solution with a potentially lower risk of rebound.
Strong Drug-like Properties and IP, Without Compromising Safety TY-3002's innovative design does not come at the cost of safety. In head-to-head continuous dosing studies in hGLP-1R DIO mouse models against Orforglipron, TY-3002 was well-tolerated across different dose groups, with no observed abnormal liver weight. Furthermore, treatment-related AST and ALT liver enzyme levels showed a slight decrease, demonstrating its hepatic safety profile. Overall, the gastrointestinal tolerability and ADME toxicology characteristics of TY-3002 are comparable to first-generation drugs, with no "red flag" signals observed to date.
The innovative design also confers a stronger intellectual property barrier and clear freedom to operate. TYK MEDICINES-B has positioned TY-3002 as a highly strategic pipeline asset and is currently advancing the project with full effort. The nomination of this next-generation GLP-1R small molecule, TY-3002, fully demonstrates TYK MEDICINES-B's leading molecular design capabilities and opens a new competitive landscape in the global field of next-generation oral weight loss medications.